Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix
Proton beam radiation therapy is known to spare surrounding normal tissues from radiation. Proton beam radiation delivers less radiation beyond the area of the target tissues. This may reduce side effects that patients would normally experience with standard (photon) radiation therapy which tends to unavoidably include more normal tissue along with tumor target tissue.
In this research study, the investigators are looking to determine if proton beam radiation is effective in controlling your cancer growth. The investigators are also looking to see if proton beam radiation can reduce side effects when compared to standard radiation treatment (photon radiation).
|Study Design:||Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix With Metastases to Regional Lymph Nodes|
- Magnitude of radiation dose reductions [ Time Frame: 5 years ]In a population of women with cancers of the cervix or endometrium with pathologically proven spread to regional lymph nodes, to quantitate the magnitude of the normal tissue radiation dose reductions achieved by comparison of dose volume histograms achieved by scanning proton beam teletherapy with dose volume histograms of treatment plans for the same patients using 3-dimensional conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT).
- Radiation side effects and delayed complications [ Time Frame: 5 years ]To prospectively assess acute radiation side effects and delayed complications in proton treated patients and to compare toxicity outcomes (acute side effects and delayed complications) with patients historically treated with photon teletherapy using institutional historical controls. (Retrospective outcomes comparison study.)
- QOL [ Time Frame: 5 years ]To prospectively collect data on quality of life (QOL) before and after adjuvant scanning proton beam therapy employing contemporary, validated instruments tailored for women treated for gynecologic cancer.
- Progression-free survival [ Time Frame: 5 years ]To determine the progression-free survival and patterns of recurrence with this treatment.
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||May 2021|
|Estimated Primary Completion Date:||May 2019 (Final data collection date for primary outcome measure)|
Proton Radiation Therapy
This is a single arm study; all participants will receive proton radiation therapy.
Radiation: Proton radiation therapy
5 days per week (Mon-Fri) for 5-6 weeks
Subjects will receive proton beam radiation treatment as an outpatient at the Francis H. Burr Proton Center at Massachusetts General Hospital, 5 days per week (Mon-Fri) over 5-6 weeks depending on the type of cancer.
Tests and procedures during study treatment (weekly):
- Questions about health and current medications
- Physical exam, includes height, weight and vital signs
- Performance status
- Blood test for complete blood counts and blood clotting (2 tsps). Repeated twice weekly for uterine cancer subjects and once weekly for cervix cancer subjects
- Pelvic exam (at week 6 only)
- Quality of life questionnaires
After completion of proton beam radiation treatment, subjects will be followed for 5 years. Follow-up visits will occur every 3 months for 2 years; every 4 months to year 3 and every 6 months thereafter. At each visit subjects will receive:
- A medical history
- Physical exam
- Performance status
- Pelvic exam
- CT scan of the chest, abdomen and pelvis every 6 months to year 3
- Quality of life questionnaires (6, 12, 24, 36, 48, and 60 months)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01600040
|Contact: Karen De Amorim Bernstein, MDfirstname.lastname@example.org|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Karen De Amorim Bernstein, MD email@example.com|
|Principal Investigator: Karen De Amorim Bernstein, MD|
|Principal Investigator:||Karen De Amorim Bernstein, MD||Massachusetts General Hospital|